A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

The first-of-its-kind Center aims to advance new treatment approaches for patients with RAS mutant cancersDana-Farber Cancer ...

Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in ...

We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and the transition into a commercial-stage company, while we continue to advance ...

Pancreatic cancer survivor Pranathi Perati talks about the importance of clinical trials for patients facing this tough ...

Excessive sugar intake can increase pancreatic cancer risk, as shown by a case of a Chinese architect diagnosed with stage 2 ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...

Oncology announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan ...

Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics, a multidisciplinary initiative to advance scientific investigation, translational research, and clinical care approaches for ...